Suven Life Sciences secures 2 product patents for NCE

20 Jun 2011 Evaluate

Suven Life Sciences, a biopharmaceutical company has secured 2 Product Patents for their NCEs in the key markets in the world.

The company has reported a decent increase of about 26.16% in the sales to Rs. 45.65 crore for the quarter ended March 2011. The sales figure stood at Rs. 36.18 crore during the year-ago period. Net Profit for the quarter ended March 2011 zoomed to 121.44% from Rs 1.58 crore to Rs. 3.50 crore. Operating Profit margin saw a handsome growth to 11.84% from 7.09% in the quarter ended March 2011.

Suven Life Science focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally-discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease. Parkinson's disease and obesity are in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.

Suven Life Sciences Share Price

170.15 -1.25 (-0.73%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×